Overview

Kidney Graft Function Under the Immunosuppression Strategies

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
To demonstrate that cyclosporine-sparing immunosuppressions with the standard dose of Enteric-Coated Mycophenolate Sodium would preserve renal graft function after transplantation without an increase of incidences of adverse events, such as biopsy confirmed acute rejection, local or systemic infections, and bone marrow suppression.
Phase:
Phase 4
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Basiliximab
Cyclosporine
Cyclosporins
Deflazacort
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Mycophenolate mofetil
Mycophenolic Acid
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate